drugset / Trial / NCT01930682

EARLY Routine Catheterization After Alteplase Fibrinolysis vs. PPCI in ST-Segment-Elevation MYOcardial Infarction

NCT01930682

Phase 4 Completed 344 enrolled RenJi Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

The EARLY-MYO (EARLY routine catheterization after alteplase fibrinolysis vs. primary PCI in acute ST-segment elevation MYOcardial infarction) is an investigator-initiated, prospective, multicenter, randomized (1:1), open-label, actively-controlled, parallel group, non-inferiority trial comparing the efficacy and safety of a PhI strategy with half-dose fibrinolysis versus PPCI in STEMI patients presenting within 6 hours after symptom onset and with an expected PCI-related delay of ≥60 min.

Timeline

Start
2014-01-13
Primary completion
2016-09
Completion
2016-09-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Alteplase Protein / enzyme biologic 42 mg Intravenous